Skip to main content
Premium Trial:

Request an Annual Quote

Rajen Dalal, John Walker, and Keith Olson

Premium

Guava Technologies president and CEO Rajen Dalal has resigned, the Hayward, Calif.-based company said last week. John Walker, the chairman of Guava’s board of directors, has taken over the company as interim CEO.

In addition to his involvement with Guava, Walker is an investment advisor to MDS Capital and a vice chairman for biotechnology company Renovis. He is also a director of Discovery Partners International, Geron, and KAI Pharmaceuticals. In the past, Walker was CEO of KAI Pharmaceuticals, Bayhill Therapeutics, Centaur Pharmaceuticals, and Axys Pharmaceuticals, Guava said.

Keith Olson, Guava’s director of product commercialization, has also left the company, Inside Bioassays has learned. Olson has taken a position with Fremont, Calif.-based drug discovery firm DiscoverX, Guava said.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.